PRESS RELEASE Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period TiGenix becomes a wholly owned subsidiary of Takeda Ordinary Shares have been delisted from Euronext Brussels The ADSs have been delisted from Nasdaq and TiGenix plans to terminate the ADS Facility and suspend its U.S. reporting obligations Osaka, Japan and Leuven, Belgium, July 31, 2018, 8 a.m. CEST - Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and TiGenix NV ("TiGenix")...